Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,120.30
(
0.16%
)
US TECH 100
25,941.64
(
0.27%
)
Dow Jones
49,597.98
(
0.30%
)
Brent Oil
93.23
(
2.81%
)
Bitcoin
75,788.85
(
-0.14%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 100536

Tuesday, 08/03/2010 1:00:01 PM

Tuesday, August 03, 2010 1:00:01 PM

Post# of 257432
AGN—It’s curious that investors are reading the tea leaves so bullishly with respect to the Botox sBLA for migraine while simultaneously ignoring the competitive threat from Xeomin, which just got FDA approval for its first indication (#msg-52866968) and has a robust phase-3 program for cosmetic indications that is nearing completion.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today